The initiation of GLP-1 agonists was associated with a lower risk for Alzheimer’s disease and related dementias than the initiation of DPP-4 inhibitors in patients with diabetes undergoing ...

Among patients with diabetes who require in-center hemodialysis, the use of GLP-1 receptor agonists is associated with a lower risk of developing Alzheimer disease and related dementias compared with ...

The study published in eClinicalMedicine by Huilin Tang and colleagues from the University of Pennsylvania Perelman School of ...

In patients with type 2 diabetes (T2D), the use of GLP-1 receptor agonists was associated with a significantly lower risk for lung cancer than the use of DPP-4 inhibitors. GLP-1 receptor agonist use ...

GLP-1 drugs show a potential link to reduced epilepsy risk in people with type 2 diabetes. People taking GLP-1 drugs were 16% less likely to develop epilepsy than those on DPP-4 inhibitors.

Risk of recurrent major adverse limb events was lower in diabetes patients taking GLP-1 agents compared with DPP-4 inhibitors. Reduction of limb events was most significant for major amputations, ...

Real-world study in type 2 diabetes suggests possible association, but more research is ne ...

Please provide your email address to receive an email when new articles are posted on . In patients with diabetes and major adverse limb events, GLP-1s conferred better outcomes than DPP-IV inhibitors ...

Those prescribed a GLP-1 RA had a significantly increased risk for new chronic cough compared with those prescribed any non-GLP-1 RA second-line medication, DPP-4 inhibitor, or sulfonylurea in a ...

GLP-1RA use improves major cardiovascular and kidney outcomes among patients with systemic lupus erythematosus and lupus nephritis. Use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) is ...